Skip to content

comparing efficacy and safety of oxytocin & misoprostol as single or combined agent on blood loss at vaginal delivery; A randomised double-blind placebo-controlled study.

Comparing efficacy and safety of oxytocin & misoprostol as single or combined agent on blood loss at vaginal delivery; A randomised double-blind placebo-controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR202507750793530
Enrollment
342
Registered
2025-07-25
Start date
2025-07-17
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy and Childbirth

Interventions

parenteral oxytocin plus 400mcg sublingual misoprostol
water for injections plus 400mcg sublingual misoprostol
parenteral 10IU oxytocin plus sublingual two tablets of placebo

Sponsors

self
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. All consenting pregnant women in the active phase of labour. 2. Estimated gestational age at term (37-42 weeks) at time of delivery.

Exclusion criteria

Exclusion criteria: 1. Women with intrapartum anaemia (Hb <8g/dl) 2. Antepartum haemorrhage 3. Pre-existing history of maternal haemorrhagic disease. 4. Recent use of antiplatelet drugs. 5. Hypersensitivity to prostaglandins 6. Women scheduled for elective cesarean section who present in the active phase of labour.

Design outcomes

Primary

MeasureTime frame
The primary outcomes will be the mean blood loss during the third stage of labour

Secondary

MeasureTime frame
This will comprise the duration of the third stage of labour, the occurrence of primary postpartum hemorrhage, significant differences between intrapartum and postpartum haemoglobin levels, retained placenta, severe postpartum hemorrhage, the need for additional uterotonics to treat life-threatening hemorrhage, blood transfusion, and medication side-effects.

Countries

Nigeria

Contacts

Public Contactabiodun Adeniran

co investigator

acrowncord@hotmail.com+2349036784788

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026